| Old Articles: <Older 7651-7660 Newer> |
|---|
 |
The Motley Fool
July 15, 2011
Brian Orelli |
Vical Transplants Some Firepower A licensing deal with Astellas gives the company a shot in the arm.   |
The Motley Fool
July 15, 2011 |
PetMed Express Earnings Preview PetMed Express will unveil its latest earnings on Monday, July 18. |
The Motley Fool
July 15, 2011
Brian Orelli |
Seattle Genetics Will Work It Out This isn't the NFL labor negotiations. |
The Motley Fool
July 15, 2011
Arundhati Parmar |
St. Jude Medical's Novel Heart Disease Diagnostic Tool Cleared in Europe St. Jude has an inventive new heart disease treatment. |
The Motley Fool
July 14, 2011
Rich Smith |
What's All the Fuss About Stem Cells? Stocks are up on news of Sweden's miracle meatball. Over the weekend, Swedish researchers announced the successful transplant of an artificial trachea to a patient whose own organ had been ravaged by cancer. |
The Motley Fool
July 13, 2011 |
Universal Health Realty Earnings Preview Universal Health Realty, Income will unveil its latest earnings on Monday, July 18. |
Chemistry World
July 14, 2011
Holly Sheahan |
No More Oxygen for Artificial Lung US scientists have mimicked the structure of a lung to make a device that can use air as a ventilating gas instead of pure oxygen. The invention could mean that implantable devices could be a step closer. |
The Motley Fool
July 14, 2011
Brian Orelli |
Good Data, but Lots of Competition Regeneron's sarilumab passes a phase 2b trial. |
The Motley Fool
July 14, 2011
Luke Timmerman |
Seattle Genetics Wins Unanimous OK for Lymphoma Drug from FDA Panel An FDA panel of cancer drug experts recommended in a 10-0 vote that the company's drug for Hodgkin's lymphoma should be cleared for sale in the U.S. |
The Motley Fool
July 14, 2011
Seth Jayson |
Here's How ZOLL Medical Is Making You So Much, So Fast On a 12-month basis, the trend at ZOLL Medical looks good. |
| <Older 7651-7660 Newer> Return to current articles. |
